Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: Targeted delivery of the therapeutic payload in an orthotopic brain tumor model

Cancer Gene Therapy

Volumn 19, Issue 6, 2012, Pages 431-442

  Thaci, B ^a   Ahmed, A U ^a   Ulasov, I V ^a   Tobias, A L ^a   Han, Y ^a   Aboody, K S ^b   Lesniak, M S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Adenovirus; carrier; cotton rat; hamster; neural stem cell; oncolytic virus

Indexed keywords

ONCOLYTIC ADENOVIRUS; VIRUS DNA;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CANCER CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; COTTON RAT; CYTOLYSIS; EX VIVO STUDY; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; LEFT HEMISPHERE; MALE; MOUSE; NEURAL STEM CELL; NONHUMAN; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PHARMACOKINETICS; PRIORITY JOURNAL; RIGHT HEMISPHERE; SYRIAN HAMSTER; TUMOR GROWTH; TUMOR MODEL; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; BRAIN; BRAIN NEOPLASMS; CELL LINE; CELL SURVIVAL; CRICETINAE; DISEASE MODELS, ANIMAL; GLIOMA; GREEN FLUORESCENT PROTEINS; HUMANS; LUCIFERASES, FIREFLY; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEURAL STEM CELLS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; ORGANISMS, GENETICALLY MODIFIED; RECOMBINANT PROTEINS; SIGMODONTINAE; VIRAL LOAD; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; CRICETINAE; MESOCRICETUS AURATUS; MUS MUSCULUS; SIGMODON;

EID: 84861195591     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.21     Document Type: Article

References (41)

1. Deorah S, Lynch CF, Sibenaller ZA, Ryken TC. Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus 2006; 20: E1.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
3. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507.
4. Sheehan JP, Shaffrey ME, Gupta B, Larner J, Rich JN, Park DM. Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. Future Oncol 2010; 6: 1591-1601.
5. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28: 4722-4729.
6. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66: 7843-7848. (Pubitemid 44299144)
7. Dey M, Ulasov IV, Tyler MA, Sonabend AM, Lesniak MS. Cancer stem cells: the final frontier for glioma virotherapy. Stem Cell Rev 2011; 7: 119-129.
8. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther 2007; 15: 651-659. (Pubitemid 46431984)
9. Ulasov IV, Zhu ZB, Tyler MA, Han Y, Rivera AA, Khramtsov A et al. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther 2007; 18: 589-602. (Pubitemid 47187091)
10. Zhu ZB, Makhija SK, Lu B, Wang M, Rivera AA, Kim-Park S et al. Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and antitumor effects in vitro and in vivo. Int J Oncol 2005; 27: 237-246.
11. Ulasov IV, Rivera AA, Sonabend AM, Rivera LB, Wang M, Zhu ZB et al. Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biol Ther 2007; 6: 679-685. (Pubitemid 47328347)
12. Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 2007; 99: 1410-1414. (Pubitemid 351767180)
13. Selznick LA, Shamji MF, Fecci P, Gromeier M, Friedman AH, Sampson J. Molecular strategies for the treatment of malignant glioma-genes, viruses, and vaccines. Neurosurg Rev 2008; 31: 141-155.
14. Chiocca EA, Aguilar LK, Bell SD, Kaur B, Hardcastle J, Cavaliere R et al. Phase IB Study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol 2011; 29: 3611-3619.
15. Tyler MA, Ulasov IV, Sonabend AM, Nandi S, Han Y, Marler S et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther 2009; 16: 262-278.
16. Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, Lesniak MS. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008; 26: 831-841.
17. Ahmed AU, Thaci B, Alexiades NG, Han Y, Qian S, Liu F et al. Neural stem cellbased cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Mol Ther 2011; 19: 1714-1726.
18. Ahmed AU, Tyler MA, Thaci B, Alexiades NG, Han Y, Ulasov IV et al. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol Pharm 2011; 8: 1559-1572.
19. Dembinski JL, Spaeth EL, Fueyo J, Gomez-Manzano C, Studeny M, Andreeff M et al. Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Ther 2010; 17: 289-297.
20. Kim SK, Kim SU, Park IH, Bang JH, Aboody KS, Wang KC et al. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin Cancer Res 2006; 12: 5550-5556. (Pubitemid 44497273)
21. Sonabend AM, Ulasov IV, Han Y, Rolle CE, Nandi S, Cao D et al. Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats. Cancer Gene Ther 2009; 16: 362-372.
22. Aboody KS, Najbauer J, Danks MK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 2008; 15: 739-752. (Pubitemid 351627357)
23. Thu MS, Najbauer J, Kendall SE, Harutyunyan I, Sangalang N, Gutova M et al. Iron labeling and pre-clinical MRI visualization of therapeutic human neural stem cells in a murine glioma model. PLoS One 2009; 4: e7218.
24. Ahmed AU, Rolle CE, Tyler MA, Han Y, Sengupta S, Wainwright DA et al. Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. Mol Ther 2010; 18: 1846-1856.
25. Power AT, Bell JC. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther 2008; 15: 772-779. (Pubitemid 351627361)
26. Toth K, Spencer JF, Tollefson AE, Kuppuswamy M, Doronin K, Lichtenstein DL et al. Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Hum Gene Ther 2005; 16: 139-146. (Pubitemid 40250340)
27. Toth K, Spencer JF, Wold WS. Immunocompetent, semi-permissive cotton rat tumor model for the evaluation of oncolytic adenoviruses. Methods Mol Med 2007; 130: 157-168.
28. Thomas MA, Spencer JF, Wold WS. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors. Methods Mol Med 2007; 130: 169-183.
29. Studebaker AW, Hutzen B, Pierson CR, Russell SJ, Galanis E, Raffel C. Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluiddisseminated medulloblastoma. Neuro Oncol 2012; 14: 459-470.
30. Lowenstein PR. Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective. Trends Immunol 2002; 23: 23-30. (Pubitemid 34098958)
31. Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 2004; 11(Suppl 1): S10-S17. (Pubitemid 39359442)
32. Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol Ther 2005; 12: 585-598. (Pubitemid 41350140)
33. Niewiesk S, Prince G. Diversifying animal models: the use of hispid cotton rats (Sigmodon hispidus) in infectious diseases. Lab Anim 2002; 36: 357-372. (Pubitemid 35192151)
34. Niewiesk S. Cotton rats (Sigmodon hispidus): an animal model to study the pathogenesis of measles virus infection. Immunol Lett 1999; 65: 47-50. (Pubitemid 29074499)
35. Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE et al. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 2007; 85: 133-148. (Pubitemid 47629395)
36. Stoica G, Lungu G, Martini-Stoica H, Waghela S, Levine J, Smith III R. Identification of cancer stem cells in dog glioblastoma. Vet Pathol 2009; 46: 391-406.
37. Ubiali F, Nava S, Nessi V, Frigerio S, Parati E, Bernasconi P et al. Allorecognition of human neural stem cells by peripheral blood lymphocytes despite low expression of MHC molecules: role of TGF-beta in modulating proliferation. Int Immunol 2007; 19: 1063-1074. (Pubitemid 47434239)
38. Ahmed AU, Alexiades NG, Lesniak MS. The use of neural stem cells in cancer gene therapy: predicting the path to the clinic. Curr Opin Mol Ther 2010; 12: 546-552.
39. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008; 6: 529-540. (Pubitemid 351850977)
40. Einstein O, Ben-Hur T. The changing face of neural stem cell therapy in neurologic diseases. Arch Neurol 2008; 65: 452-456. (Pubitemid 351549952)
41. Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 2003; 422: 688-694. (Pubitemid 36514101)